Boji Medical's "Qingzhi Ointment" enters clinical trials for knee osteoarthritis

Guangzhou Boji Medical & Biotechnological Co., Ltd. announced that its wholly-owned subsidiary, Guangzhou Boji New Drug Clinical Research Center Co., Ltd., has secured approval for the clinical trial of "Qingzhi Ointment" from the National Medical Products Administration. The approval confirms the ointment meets drug registration requirements and can proceed with clinical trials for knee osteoarthritis.

"Qingzhi Ointment" is an innovative traditional Chinese medicine, classified as a Class 1.1 new traditional Chinese medicine formulation not yet marketed domestically or internationally. It is formulated from multiple herbal ingredients based on traditional Chinese medicine theories, indicated for wind-cold-dampness arthralgia of the knee, aiming to dispel wind, overcome dampness, disperse cold, and promote qi circulation to relieve pain.

The company cautioned that this approval is a preliminary achievement in new drug research and development and will not significantly impact its operating performance. Due to the inherent uncertainties of drug development, the progress and outcomes of clinical trials, as well as future market competitiveness, remain uncertain. Investors are advised to exercise caution and be aware of investment risks.